Education
About Us
Working with TipRanks
Follow Us
Newamsterdam Pharma Company N.V. (NAMS)
:NAMS
RESEARCH TOOLSreports
NAMS Analyst Ratings
Strong Buy
10 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
NAMS Stock 12 Month Forecast
Average Price Target
$43.50
▲(138.75%Upside)
| Highest Price Target$52.00 | Average Price Target$43.50 | Lowest Price Target$38.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
TipRanks
$19
Hold
4.28%
Upside
Reiterated
06/18/25
The overall stock score reflects significant positive corporate events and developments in clinical trials, offset by financial performance challenges and valuation concerns. While technical analysis suggests potential medium-term strength, the company's financial challenges and unprofitable status weigh on its valuation.
Citi
$42
Buy
130.52%
Upside
Initiated
06/18/25
Leerink Partners
$44→$45
Buy
146.98%
Upside
Reiterated
06/16/25
Stifel Nicolaus
$44
Buy
141.49%
Upside
Initiated
06/12/25
Scotiabank
$52
Buy
185.40%
Upside
Reiterated
06/12/25
TD Cowen
―
Buy
―
Reiterated
06/12/25
Needham
$40
Buy
119.54%
Upside
Reiterated
06/11/25
RBC Capital
$38
Buy
108.56%
Upside
Reiterated
06/11/25
Jefferies
$45
Buy
146.98%
Upside
Reiterated
06/11/25
William Blair
―
Buy
―
Reiterated
06/09/25
Cantor Fitzgerald
$42
Buy
130.52%
Upside
Initiated
06/04/25
Piper Sandler
$37
Buy
103.07%
Upside
Reiterated
04/01/25
Guggenheim
$35→$41
Buy
125.03%
Upside
Reiterated
03/03/25
H.C. Wainwright
$48
Buy
163.45%
Upside
Reiterated
01/14/25
Promising Outlook for NewAmsterdam Pharma: Ed Arce's Buy Rating Backed by Strategic Developments and Phase 3 SuccessesWe employ a risk-adjusted NPV (rNPV) valuation model to estimate the value of NAMS shares, and arrive at our $48 PT based on: (1) about $29 per share for U.S. net sales and EU royalties on obicetrapib in secondary ASCVD prevention (assume commercial launch in 1H27; 85% PoS; $4.7B global peak revenues in 2042); and (2) about $19 per share as a placeholder value for obicetrapib in primary ASCVD prevention (about 40% larger opportunity than secondary prevention; 40% PoS). In our valuation model, we employ a 12.0% discount rate, which we believe adequately reflects the overall risks facing NewAmsterdam.
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
TipRanks
$19
Hold
4.28%
Upside
Reiterated
06/18/25
The overall stock score reflects significant positive corporate events and developments in clinical trials, offset by financial performance challenges and valuation concerns. While technical analysis suggests potential medium-term strength, the company's financial challenges and unprofitable status weigh on its valuation.
Citi
$42
Buy
130.52%
Upside
Initiated
06/18/25
Leerink Partners
$44→$45
Buy
146.98%
Upside
Reiterated
06/16/25
Stifel Nicolaus
$44
Buy
141.49%
Upside
Initiated
06/12/25
Scotiabank
$52
Buy
185.40%
Upside
Reiterated
06/12/25
TD Cowen
―
Buy
―
Reiterated
06/12/25
Needham
$40
Buy
119.54%
Upside
Reiterated
06/11/25
RBC Capital
$38
Buy
108.56%
Upside
Reiterated
06/11/25
Jefferies
$45
Buy
146.98%
Upside
Reiterated
06/11/25
William Blair
―
Buy
―
Reiterated
06/09/25
Cantor Fitzgerald
$42
Buy
130.52%
Upside
Initiated
06/04/25
Piper Sandler
$37
Buy
103.07%
Upside
Reiterated
04/01/25
Guggenheim
$35→$41
Buy
125.03%
Upside
Reiterated
03/03/25
H.C. Wainwright
$48
Buy
163.45%
Upside
Reiterated
01/14/25
Promising Outlook for NewAmsterdam Pharma: Ed Arce's Buy Rating Backed by Strategic Developments and Phase 3 SuccessesWe employ a risk-adjusted NPV (rNPV) valuation model to estimate the value of NAMS shares, and arrive at our $48 PT based on: (1) about $29 per share for U.S. net sales and EU royalties on obicetrapib in secondary ASCVD prevention (assume commercial launch in 1H27; 85% PoS; $4.7B global peak revenues in 2042); and (2) about $19 per share as a placeholder value for obicetrapib in primary ASCVD prevention (about 40% larger opportunity than secondary prevention; 40% PoS). In our valuation model, we employ a 12.0% discount rate, which we believe adequately reflects the overall risks facing NewAmsterdam.
Best Analysts Covering NewAmsterdam Pharma Company
1 Month
xxx
Success Rate
7/11 ratings generated profit
Average Return
-1.15%
reiterated a xxx
rating 22 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 63.64% of your transactions generating a profit, with an average return of -1.15% per trade.
3 Months
xxx
Success Rate
4/8 ratings generated profit
Average Return
+7.15%
reiterated a xxx
rating 3 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 50.00% of your transactions generating a profit, with an average return of +7.15% per trade.
1 Year
Success Rate
9/19 ratings generated profit
Average Return
+21.66%
reiterated a buy rating 17 days ago
Copying Roanna Ruiz's trades and holding each position for 1 Year would result in 47.37% of your transactions generating a profit, with an average return of +21.66% per trade.
2 Years
xxx
Success Rate
6/11 ratings generated profit
Average Return
+30.55%
reiterated a xxx
rating 22 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 54.55% of your transactions generating a profit, with an average return of +30.55% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
NAMS Analyst Recommendation Trends
Rating
Feb 25
Mar 25
Apr 25
May 25
Jun 25
Strong Buy
14
9
9
11
19
Buy
4
4
4
4
7
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
18
13
13
15
26
Each month's total comprises the sum of three months' worth of ratings.
NAMS Financial Forecast
NAMS Stock Forecast FAQ
What is NAMS’s average 12-month price target, according to analysts?
Based on analyst ratings, Newamsterdam Pharma Company N.V.’s 12-month average price target is 43.50.
What is NAMS’s upside potential, based on the analysts’ average price target?
Newamsterdam Pharma Company N.V. has 138.75% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is NAMS a Buy, Sell or Hold?
Newamsterdam Pharma Company N.V. has a consensus rating of Strong Buy which is based on 10 buy ratings, 0 hold ratings and 0 sell ratings.
What is Newamsterdam Pharma Company N.V.’s price target?
The average price target for Newamsterdam Pharma Company N.V. is 43.50. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $52.00 ,the lowest forecast is $38.00. The average price target represents 138.75% Increase from the current price of $18.22.
The highest analyst price target is $52.00 ,the lowest forecast is $38.00. The average price target represents 138.75% Increase from the current price of $18.22.
What do analysts say about Newamsterdam Pharma Company N.V.?
Newamsterdam Pharma Company N.V.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 10 Wall Streets Analysts.
How can I buy shares of NAMS?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.